Piribedil

Jump to: navigation, search
Piribedil
Piribedil Wiki Str.png
Clinical data
Routes of
administration
Oral
ATC code
Pharmacokinetic data
Elimination half-life1.7 – 6.9 hours
ExcretionRenal (68%) and biliary (25%)
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC16H18N4O2
Molar mass298.340 g/mol

WikiDoc Resources for Piribedil

Articles

Most recent articles on Piribedil

Most cited articles on Piribedil

Review articles on Piribedil

Articles on Piribedil in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Piribedil

Images of Piribedil

Photos of Piribedil

Podcasts & MP3s on Piribedil

Videos on Piribedil

Evidence Based Medicine

Cochrane Collaboration on Piribedil

Bandolier on Piribedil

TRIP on Piribedil

Clinical Trials

Ongoing Trials on Piribedil at Clinical Trials.gov

Trial results on Piribedil

Clinical Trials on Piribedil at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Piribedil

NICE Guidance on Piribedil

NHS PRODIGY Guidance

FDA on Piribedil

CDC on Piribedil

Books

Books on Piribedil

News

Piribedil in the news

Be alerted to news on Piribedil

News trends on Piribedil

Commentary

Blogs on Piribedil

Definitions

Definitions of Piribedil

Patient Resources / Community

Patient resources on Piribedil

Discussion groups on Piribedil

Patient Handouts on Piribedil

Directions to Hospitals Treating Piribedil

Risk calculators and risk factors for Piribedil

Healthcare Provider Resources

Symptoms of Piribedil

Causes & Risk Factors for Piribedil

Diagnostic studies for Piribedil

Treatment of Piribedil

Continuing Medical Education (CME)

CME Programs on Piribedil

International

Piribedil en Espanol

Piribedil en Francais

Business

Piribedil in the Marketplace

Patents on Piribedil

Experimental / Informatics

List of terms related to Piribedil

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Piribedil is a piperazine dopamine agonist; and marketed as TRIVASTAL Retard 50.

Trivastal retard 50 is also distributed as: Trastal, Trivastal 50 retard, Trivastal 50mg LP, Trivastan ritardo and Pronoran.


Composition:

Piribedil 50 mg per tablet - sustained-release.


Indications:

- Treatment of Parkinson's disease, either as monotherapy (without L-dopa) or in combination with L-dopa therapy, in the early stages as well as in the advanced stages. - Treatment of pathological cognitive deficits in the elderly (impaired attention, memory, etc). Treatment of dizziness in the elderly. - Treatment of Retinal ischemic manifestations. Adjuvant treatment in intermittent claudication due to peripheral occlusive arterial disease of the lower limbs (stage 2). - (off label) anhedonia and treatment-resistant depression in unipolar and bipolar depressives

Dosage:

In Parkinson's disease: administration of Trivastal retard 50 should be initiated with 1 tablet daily during the first week. Dosage should then be gradually increased every week until achieving the optimal therapeutic dose: as monotherapy: 3 to 5 tablets in 3 to 5 divided doses daily. In combination with L-dopa therapy: 1 to 3 tablets daily. In other indications: 1 tablet daily at the end of the main meal. In severe cases: 2 tablets daily as 2 divided doses.

Trivastal retard 50 is a nonergot dopamine agonist, selective for D2 and D3 dopamine receptors subtypes at the cerebral and at the peripheral level.

Cardiogenic shock. Acute phase of myocardial infarction.

Adverse:

rare side effects: minor gastrointestinal disorders (nausea, vomiting, flatulence) in predisposed individuals, or when taken between meals. They may resolve with the following: individual dosage adjustment, and/or addition of domperidone. Orthostatic hypotension or drowsiness may occur, particularly in predisposed individuals (underlying condition or causative illness).

Dopaminergic antagonists.


Overdosage:

At very high doses, Trivastal retard 50 has an emetic action on the CTZ (chemoreceptive trigger zone). Tablets will thus be rapidly rejected, which explains why no data are currently available concerning the risk of overdosage.



Template:Drug-stub


Linked-in.jpg